The goal of this study is to test the efficacy of Dupixent in improving post-burn itching symptoms versus the current standard of care.
Participants will receive six injections of Dupixent or placebo (two 300 mg loading doses and one 300 mg dose every two weeks after that). In addition, participants will be asked to complete questionnaires to determine daily itch severity, quality of life, treatment benefit, physical functioning, and pain interference. Individual participants will require 13 weeks to complete all study visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
46
Akron Children's Hospital
Akron, Ohio, United States
RECRUITINGItch Severity Scale (ISS) Scores
Participants' Itch Severity Scale (ISS) scores will decrease more than 2.0 points after 12 weeks following initiating use of Dupixent
Time frame: 12 WEEKS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.